Diabetic foot is one of the most serious complications of diabetes, and is associated with significant portions of admission, medical cost, disability and mortality in diabetic patients. According to a recent report from the Korean Diabetes Association Basic Statistics Research Task Force Team, 1.2% of Korean diabetic patients had diabetic foot, representing a decrease since 1980. The age at amputation increased since 1980, from 60 to 70 years of age, while the mortality rate decreased due to advances of therapeutic technology. Further epidemiologic studies are required to obtain current data regarding incidence, amputation rates, and mortality, and to identify risk factors and new therapeutic modalities in diabetic foot. (J Korean Diabetes 2011;12:69-71) 
Grade Stage bacitracin, tretinoin tocoferil (Olcenon Ⓡ )], 전접촉 석고붕대(total contact cast, TCC), mechanical offloading devices (wheelchair, crutches, Scotchcast boot, TCC)를 주로 시행하였으나 최근에는 그밖에도 n e g a t i v e p r e s s u r e w o u n d t h e r a p y (NPWT)[vacuum-assisted closure (VAC Ⓡ ) 요법], 고압산소요법(HBO), larval therapy (maggots), 성장인자[rhPDGF-BB (becaplermin, Regranex Ⓡ ), platelet derived wound healing factors (Procuren Ⓡ ), EGF (Easy-F Ⓡ ), G-CSF], polydeoxyribonucleotide (PDRN) [11] , platelet-rich plasma (PRP) [12] , living tissue engineered products (Dermograft Ⓡ , Apligraf Ⓡ ) [13] , bioengineered skin (BS) [14] , stem cells (BM-derived MSC, adipose-derived SC) [ 
